Article
Medicine, General & Internal
Jun Dang, Yutang Yao, Yingchun Li, Xiaofei Tan, Zhenyan Ye, Yi Zhao, Shiwei Qing, Ying Kou, Xiao Jiang, Hao Lu, Shirong Chen, Meng Zhao, Zhuzhong Cheng
Summary: This study aimed to explore the cause of bladder concentration of F-18-PSMA-1007 by assessing the clinical and imaging characteristics, but found no correlation. Further studies are needed to find explanations and improve the disease assessment of prostate cancer patients.
FRONTIERS IN MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Clemens Mingels, Karl Peter Bohn, Axel Rominger, Ali Afshar-Oromieh, Ian Alberts
Summary: This study investigated the diagnostic accuracy of [F-18]PSMA-1007 PET/CT in biochemically recurrent prostate cancer. The results showed good performance in terms of regional sensitivity and negative predictive value, but limited positive predictive value, especially for bone lesions.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Oncology
Ioana M. Marinescu, Simon K. B. Spohn, Selina Kiefer, Peter Bronsert, Lara Ceci, Julius Holzschuh, August Sigle, Cordula A. Jilg, Alexander Ruehle, Tanja Sprave, Nils H. Nicolay, Robert Winzer, Jana Rehm, Joerg Kotzerke, Tobias Hoelscher, Anca L. Grosu, Juri Ruf, Matthias Benndorf, Constantinos Zamboglou
Summary: This study compares the performance of multiparametric resonance imaging (mpMRI) with [F-18] PSMA-1007 positron emission tomography (PET) for the detection and delineation of intraprostatic gross tumor volume (GTV) in primary prostate cancer (PCa), and evaluates their respective influence on radiotherapy (RT) concepts.
FRONTIERS IN ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Freba Grawe, Franziska Blom, Michael Winkelmann, Caroline Burgard, Christine Schmid-Tannwald, Lena M. Unterrainer, Gabriel T. Sheikh, Paulo L. Pfitzinger, Philipp Kazmierczak, Clemens C. Cyran, Jens Ricke, Christian G. Stief, Peter Bartenstein, Johannes Ruebenthaler, Matthias P. Fabritius, Thomas Geyer
Summary: PSMA-RADS 1.0 is a reliable method for assessing PSMA-PET/CT with strong consistency and agreement among readers. It shows great potential for establishing a standard approach to diagnosing and planning treatment for prostate cancer patients, and can be used confidently even by readers with less experience.
EUROPEAN RADIOLOGY
(2023)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Fatih Tamer, Ozgur Omur
Summary: A 59-year-old man with a history of prostate cancer underwent a radical prostatectomy in 2009. Due to rising PSA levels, he underwent a Ga-68-PSMA PET/CT scan in January 2020, which revealed suspicious uptake in the left cerebellar hemisphere. There was no evidence of distant metastases, except for recurrent malignancy at the prostatectomy site. Further MRI showed a meningioma in the left cerebellopontine angle. Although PSMA uptake initially increased after hormone therapy, partial regression was observed after radiotherapy in the affected region.
CLINICAL NUCLEAR MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
R. Gallicchio, A. Nardelli, G. Calice, A. Guarini, G. Guglielmi, G. Storto
Summary: This study evaluated the prognostic significance of combined use of FDG and FLT PET/CT in MM patients, showing that PET/CT can predict patient prognosis and that FDG+; FLT- patients have better EFS compared to other groups.
EUROPEAN JOURNAL OF RADIOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ian Alberts, Jan-Niklas Huenermund, Christos Sachpekidis, Clemens Mingels, Viktor Fech, Karl Peter Bohn, Axel Rominger, Ali Afshar-Oromieh
Summary: Digital PET/CT demonstrated a higher detection rate for pathological lesions compared with analogue PET/CT, with an improved true-positive rate and without increased diagnostic uncertainty, rate of non-specific lesions, or reduced interrater reliability.
EUROPEAN RADIOLOGY
(2021)
Article
Oncology
Wenxiao Yu, Ming Zhao, Yingjun Deng, Shengjing Liu, Guanchao Du, Bin Yan, Ziwei Zhao, Ning Sun, Jun Guo
Summary: This study compared the diagnostic value of (18) F-PSMA-1007 PET/CT, (18) F-FDG PET/CT, and Ga-68-PSMA PET/CT in prostate cancer. The results showed that both (18) F-PSMA-1007 PET/CT and Ga-68 PSMA PET/CT demonstrated higher diagnostic efficacy compared to (18) F-FDG PET/CT.
Article
Oncology
Siying Dong, Yanmei Li, Jian Chen, Yongliang Li, Pengfei Yang, Juan Li
Summary: This study evaluated the value of semi-quantitative parameters derived from F-18-PSMA-1007 PET/CT imaging for risk stratification in newly diagnosed prostate cancer. TL-PSMAp was found to have a superior ability to identify high-risk prostate cancer. These imaging parameters can serve as objective reference indices for determining prostate cancer risk stratification.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Siroos Mirzaei, Rainer Lipp, Shahin Zandieh, Asha Leisser
Summary: The diagnostic performance of [Cu-64]-DOTAGA-PSMA PET-CT imaging was compared to [F-18]-PSMA PET-CT in prostate cancer patients. Both radiotracers showed comparable detection rates, with slight differences in liver uptake.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Amanda Nguyen, Felipe Martinez, Ba D. Nguyen
Summary: This case report presents chest wall keloids detected on F-18-piflufolastat PET/CT during the evaluation of prostate cancer recurrence.
CLINICAL NUCLEAR MEDICINE
(2023)
Article
Oncology
Suk-Hyun Lee, Jee-Soo Park, Hyunjeong Kim, Dongwoo Kim, Seung-Hwan Lee, Won-Sik Ham, Woong-Kyu Han, Young-Deuk Choi, Mijin Yun
Summary: The heterogeneous uptake of both F-18 FDG and C-11 methionine on PET/CT in renal cell carcinomas is associated with higher grades of cancer. The metabolic tumour volume on F-18 FDG PET/CT but not C-11 methionine PET/CT is significant in predicting advanced-stage renal cell carcinoma. These metabolic features derived from PET/CT imaging may aid in the development of new drugs targeting glucose and amino acid metabolic pathways.
Article
Medicine, General & Internal
Manuela A. Hoffmann, Jonas Mueller-Huebenthal, Florian Rosar, Nicolas Fischer, Finn Edler von Eyben, Hans-Georg Buchholz, Helmut J. Wieler, Mathias Schreckenberger
Summary: This study compared the performance of [F-18]PSMA-1007 and [Ga-68]Ga-PSMA-11 positron emission tomography/computed tomography in the initial staging of prostate cancer patients. The results showed that both methods were able to detect PSMA-avid lesions with high concordance to histopathologically proven cancer. There was no superior advantage of either method in diagnosing prostate cancer.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Stephan P. M. Souza, Fernanda C. Frasson, Maria Emilia S. Takahashi, Gislaine B. O. Duarte, Vania P. Castro, Fernando V. Pericole, Licio A. Velloso, Carmino A. De Souza, Irene Lorand-Metze, Allan O. Santos, Celso D. Ramos
Summary: The aim of this study was to compare [F-18]FDG and [Ga-68]Ga-PSMA-11 PET/CT image findings in patients with multiple myeloma (MM). The study found that both methods can detect most lesions, but half of the lesions can only be identified by one tracer, suggesting their possible complementary role in MM.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Florian Rosar, Fadi Khreish, Robert J. Marlowe, Andrea Schaefer-Schuler, Caroline Burgard, Stephan Maus, Sven Petto, Mark Bartholomae, Samer Ezziddin
Summary: Preliminary data suggest that using Zr-89-labeled PSMA ligand radiotracers may be more effective than using tracers with short-lived radionuclides in detecting suspicious lesions in patients with biochemical recurrence of prostate cancer. In this study, 78% of patients had suspicious lesions detected on 24-h and 48-h scans, with higher detection rates on the 48-h scans. This suggests that imaging at a later time may be preferable.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Chemistry, Medicinal
Florian Brandt, Martin Ullrich, Johanna Wodtke, Klaus Kopka, Michael Bachmann, Reik Loeser, Jens Pietzsch, Hans-Juergen Pietzsch, Robert Wodtke
Summary: The use of radioligands for targeted endoradionuclide therapy is limited due to their toxicity to healthy tissues, specifically the kidneys. However, targeting enzymes in the renal brush border membrane using cleavable linkers that can form fast clearing radionuclide fragments is gaining interest. In this study, a library of 64Cu-labeled cleavable linkers was synthesized and their substrate potentials towards neprilysin (NEP) were quantified, leading to the establishment of structure-activity relationships. It was found that a substrate-based targeting of NEP in the kidneys with small peptides resulted in premature cleavage in the bloodstream, highlighting the importance of additional targeting of albumin for kidney-specific NEP targeting.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
E. Mamlins, D. Schmitt, M. Beu, K. Mattes-Gyoergy, J. M. Henke, C. Antke, E. Novruzov, J. Cardinale, J. Kirchner, G. Niegisch, J. P. Radtke, L. Schimmoeller, P. Albers, G. Antoch, F. L. Giesel
Summary: This retrospective study aimed to investigate the uptake of [F-18]PSMA-1007 in ganglia of the sympathetic trunk and its intra-individual reproducibility. The results showed a good intra-individual reproducibility of [F-18]PSMA-1007 uptake in ganglia, which can help differentiate them from possible malignant lesions.
MOLECULAR IMAGING AND BIOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Ali Afshar-Oromieh, Matthias Eiber, Wolfgang Fendler, Matthias Schmidt, Kambiz Rahbar, Hojjat Ahmadzadehfar, Lale Umutlu, Boris Hadaschik, Oliver W. Hakenberg, Paolo Fornara, Jens Kurth, O. Neels, Hans-Juergen Wester, Markus Schwaiger, Klaus Kopka, Uwe Haberkorn, Ken Herrmann, Bernd J. Krause
Summary: PSMA-PET/CT has been widely used for imaging prostate cancer globally, especially for recurrent prostate cancer. Promising results have been obtained for primary staging of high-risk prostate cancer. Multiple PSMA-ligands are available for clinical use, but only (68) Ga-PSMA-11 and (18) F-DCFPyL have official approval. Late imaging can help clarify unclear findings as the contrast in PSMA-PET/CT increases with time. PSMA-PET/CT should be performed before starting androgen deprivation therapy (ADT) due to reduced visibility of PC lesions with (long term) ADT. Hydration and forced diuresis are recommended for PSMA-ligands excreted primarily via the kidneys to increase visibility of tumor lesions adjacent to the urinary bladder. PSMA-ligands are taken up in multiple normal organs and can show unspecific focal bone uptake with certain (18) F-labeled PSMA-ligands. PSMA is expressed in the neovasculature of practically all solid tumors, although usually to a lesser extent than in PC. Multiple benign lesions and inflammatory processes also take up PSMA-ligands, usually to a lesser extent than PC.
NUKLEARMEDIZIN-NUCLEAR MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yuriko Mori, Katharina Dendl, Jens Cardinale, Clemens Kratochwil, Frederik L. Giesel, Uwe Haberkorn
Summary: Gallium 68 (68Ga)-labeled fibroblast activation protein (FAP) inhibitor (FAPI) PET is a molecular imaging method that targets FAP, which is highly expressed in cancer-associated fibroblasts in the tumor stroma. Among various FAP-targeted radiopharmaceuticals, 68Ga-FAPI shows excellent imaging features with rapid tracer accumulation in target lesions and low background signal. It can detect small primary or metastatic lesions, especially in the brain, liver, pancreas, and gastrointestinal tract. Moreover, it can be used for theranostic applications by coupling with therapeutic emitters such as yttrium-90 using the DOTA chelator in its molecular structure.
Article
Medicine, Research & Experimental
Martin Ullrich, Susan Richter, Josephine Liers, Stephan Drukewitz, Markus Friedemann, Joerg Kotzerke, Christian G. Ziegler, Svenja Noelting, Klaus Kopka, Jens Pietzsch
Summary: This study evaluates the effects of epigenetic drugs on SSTR2 levels and sensitivity to [177Lu]Lu-DOTA-TATE in mouse pheochromocytoma models, and found that epigenetic drugs have a therapeutic benefit, although the exact mechanism is unknown.
Review
Urology & Nephrology
Moritz Maas, Tilman Todenhoefer, Peter C. Black
Summary: The detection of bladder cancer through urine markers has been a long-standing research topic. While the idea of urine as a vector of tumor information is attractive, the use of urine markers in clinical practice is currently limited despite the availability of numerous markers and efforts in research and development. Prospective trials are underway to increase the evidence on urinary biomarkers in bladder cancer and promote their implementation in guidelines. This Review provides a comprehensive overview of current status, limitations, and future perspectives of urine markers.
NATURE REVIEWS UROLOGY
(2023)
Article
Oncology
Fabian Krutzek, Cornelius K. K. Donat, Martin Ullrich, Kristof Zarschler, Marie-Charlotte Ludik, Anja Feldmann, Liliana R. R. Loureiro, Klaus Kopka, Sven Stadlbauer
Summary: PD-L1 plays a crucial role in immune responses against cancer. Nine small-molecule PD-L1 radiotracers with strong binding affinity have been synthesized, laying a promising foundation for the further development of PD-L1 small molecule PET radiotracers.
Article
Chemistry, Medicinal
Santiago Andres Bruehlmann, Martin Walther, Martin Kreller, Falco Reissig, Hans-Juergen Pietzsch, Torsten Kniess, Klaus Kopka
Summary: Theranostic matched pairs of radionuclides, including copper isotopes Cu-61, Cu-64, and Cu-67, have gained attention for their potential in diagnostic and therapeutic applications. Cu-67, in particular, plays a crucial role in future radiopharmaceutical development. This study focuses on producing high-purity Cu-67 using a 30MeV compact cyclotron and the Zn-70(p,alpha)Cu-67 reaction. Proton irradiation of Zn-70 targets and solid-phase extraction were used to achieve radionuclidic purities over 99.5% and apparent molar activities of up to 80MBq/nmol.
Article
Chemistry, Medicinal
Carsten Sven Kramer, Thines Kanagasundaram, Jessica Matthias, Klaus Kopka
Summary: Tracers for bimodal optical imaging and positron emission tomography combine various advantages into one molecule. These tracers can be used for tumor-specific visualization in PET/CT or PET/MRI, as well as intraoperative fluorescence-guided surgery and histological assessments. The introduction of a fluorinated silicon pyronine allows for PET activation and successful radiochemical conversion. Additionally, a library of red-shifted silicon rhodamines with different functionalizations was synthesized and their optical properties were characterized.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Marianne Patt, Clemens Decristoforo, Amelie de Martini, Michel Koole, Wim J. G. Oyen, Oliver C. Kiss
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Urology & Nephrology
Peter C. Black, Catherine M. Tangen, Parminder Singh, David J. McConkey, M. Scott Lucia, William T. Lowrance, Vadim S. Koshkin, Kelly L. Stratton, Trinity J. Bivalacqua, Wassim Kassouf, Sima P. Porten, Rick Bangs, Melissa Plets, Ian M. Thompson, Seth P. Lerner
Summary: This study evaluated the efficacy and safety of atezolizumab in BCG-unresponsive high-risk NMIBC patients who were ineligible for or declined surgery. The results showed that atezolizumab had a good pathological complete response rate in patients with carcinoma in situ, and some patients had durable responses. However, there were severe treatment-related adverse events in some patients.
Article
Oncology
Siamak Daneshmand, Clint Cary, Timothy Masterson, Lawrence Einhorn, Nabil Adra, Stephen A. Boorjian, Christian Kollmannsberger, Anne Schuckman, Alan So, Peter Black, Aditya Bagrodia, Eila Skinner, Mehrdad Alemozaffar, Timothy Brand, Scott Eggener, Phillip Pierorazio, Kelly Stratton, Lucia Nappi, Craig Nichols, Chunqiao Luo, Ming Li, Brian Hu
Summary: This study aimed to investigate the efficacy of RPLND as a first-line treatment for testicular seminoma with clinically low-volume retroperitoneal lymphadenopathy. The results showed that the 2-year recurrence-free survival rate was 81%, the recurrence rate was 22%, and the 2-year overall survival rate was 100%. The study concluded that RPLND is a viable treatment option with low long-term morbidity.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Barbara Wenzel, Maximilian Schmid, Rodrigo Teodoro, Rares-Petru Moldovan, Thu Hang Lai, Franziska Mitrach, Klaus Kopka, Bjoern Fischer, Michaela Schulz-Siegmund, Peter Brust, Michael C. Hacker
Summary: This study presents the synthesis, radiofluorination, and purification process of an anionic amphiphilic teroligomer, which serves as a stabilizer for siRNA-loaded calcium phosphate nanoparticles (CaP-NPs). The F-18-labeled polymer enables the tracking of the distribution of CaP-NPs in brain tumors through positron emission tomography. The synthesis involved the production of an unmodified teroligomer and subsequent derivatization, followed by F-18-labeling using copper-catalyzed cycloaddition. Purification was achieved through solid-phase extraction and size-exclusion chromatography.
Article
Chemistry, Inorganic & Nuclear
Marlene Schlesinger, Christian Jentschel, Hans-Juergen Pietzsch, Klaus Kopka, Constantin Mamat
Summary: Click chemistry, especially copper-free click reactions, has gained significant attention in the field of radiopharmaceutical sciences for radiolabelling purposes. This study investigated a new chelator for strain-promoted cycloaddition (SPAAC) without the need for copper, and compared it with a conventional chelator for radiolabelling. The results showed that the new chelator, containing the 2,2'-dipicolylamine (DPA) moiety, was successful in radiolabelling under mild conditions.
DALTON TRANSACTIONS
(2023)
